January 26, 2015 9:03 PM ET


Company Overview of Ascenta Therapeutics, Inc.

Company Overview

Ascenta Therapeutics, Inc. discovers and develops medicines for the treatment of cancer. Its technology consists of agents designed to re-establish the program of apoptosis (cell death) in abnormal cancer cells. The company’s products include AT-101, a pan Bcl-2 inhibitor that directly induces apoptosis by operating as a BH3 mimetic and indirectly as a p53-independent upregulator of Noxa and Puma; AT-406, a multi-inhibitor of apoptosis protein (IAP) antagonist that promotes programmed cell death (apoptosis) in tumor cells by blocking the activity of inhibitors of apoptosis proteins or IAPs, such as XIAP, c-IAP1, c-IAP2, and ML-IAP to create conditions in which apoptosis can proceed; and Huma...

101 Lindenwood Drive

Suite 405

Malvern, PA 19355

United States

Founded in 2003





Key Executives for Ascenta Therapeutics, Inc.

Co-Founder and Director
Age: 69
Vice President of Intellectual Property
Associate Director of Clinical Operations
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Applied Pharma Research USA, LLC United States
Psyadon Pharmaceuticals, Inc. United States
T&L Pharmacies, Inc. United States
InterNutria, Inc. United States
DiagnoSearch Life Sciences Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ascenta Therapeutics, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.